VERO Biotech’s Genosyl secures FDA emergency use access

27 March 2020 (Last Updated March 27th, 2020 14:00)

Biotechnology firm VERO Biotech has received expanded access emergency use from the US Food and Drug Administration (FDA) for its Genosyl DS to treat cardiopulmonary symptoms caused by Covid-19.

Previously, the FDA approved Genosyl, inhaled nitric oxide (iNO), for treating persistent pulmonary hypertension of the newborn (PPHN).

Genosyl DS is an iNO delivery system expected to aid during the short supply of hospital beds and ventilators.